Nurix Therapeutics, Inc. plans to conduct meetings with analysts and investors to present updated guidance on their clinical programs and Phase 1 trial for NX-2127.
AI Assistant
NURIX THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.